Zomedica Corp., a veterinary health company offering diagnostic and therapeutic solutions for equine and companion animals, announced a collaboration with Boehringer Ingelheim Animal Health USA Inc., a global leader in the animal health industry, to enhance early detection along with treatment and monitoring of pituitary pars intermedia dysfunction (PPID) in horses.The collaboration integrates the TRUFORMA system into Boehringer Ingelheims idPPID awareness and testing program, enabling veterinarians to perform rapid endocrine testing at the point of care using Zomedicas equine endogenous ACTH (eACTH) and equine insulin assays.This collaboration will now enable veterinarians to perform rapid endocrine testing at the point of care that fosters prompt diagnosis and treatment. The integration of Zomedicas TRUFORMA diagnostic platform into the Boehringer Ingelheim idPPID awareness and testing program brings advantages for veterinarians and horse owners, alike.Under the agreement, Zomedica will promote the idPPID program to veterinarians within its TRUFORMA and PulseVetcustomer networks, while Boehringer Ingelheim will expand its PPID testing program to include reimbursing participating veterinarians for diagnostic testing performed with Zomedicas TRUFORMA platform and reimbursement through laboratory testing at Cornell University.Participation in the program requires no-cost placement of TRUFORMA analyzers in equine veterinary practices along with the diagnostic cartridge kits reimbursed by Boehringer, expanding the installed base of Zomedicas platform and enabling the veterinarian to reorder both the initial cartridges and the remaining equine assays available from Zomedica, including Cortisol and Progesterone.PPID, previously known as equine Cushings disease, is the most common endocrine disorder in aging horses, affecting approximately 20-25% of horses over the age of 15. This prevalence has been documented in multiple epidemiological studies, including research published in theJournal of Veterinary Internal Medicine, which reported that roughly one-fifth of horses over 15 years of age show evidence of PPID based on endocrine testing (McFarlane et al.,Journal of Veterinary Internal Medicine, 2018).The program will utilize Zomedicas TRUFORMAequine endogenous ACTH (eACTH) assay, which recent comparative evaluation data has demonstrated to have the closest agreement to reference laboratory results when compared with other commercially available assays, supporting its reliability for diagnosing PPID and monitoring treatment response.Collaborating with Boehringer Ingelheim-one of the largest and most respected companies in global animal health-represents a major milestone for Zomedica, said Larry Heaton, Chief Executive Officer of Zomedica. Their leadership in equine medicine combined with our TRUFORMA diagnostic technology creates a powerful synergy and is another critical step in our strategy.Veterinarians play a critical role in recognizing and managing PPID, and weve seen the meaningful difference that early diagnosis, treatment and whole-horse management can make,said Dwana Neal, Executive Director, US Equine Business at Boehringer Ingelheim.By collaborating with Zomedica, were expanding access to innovative diagnostic solutions and empowering veterinarians to make faster, more confident decisions-ultimately supporting better outcomes for the horses in their care, and their owners.